0
Orphan Designations
5
FDA Approvals
Latest: GLYCEROL PHENYLBUTYRATE (2013)
3
Active Trials
200 recruiting
4
Rare Diseases
across 7 areas
0
News (30d)
Quiet
Lupin Pharmaceuticals, Inc. is a company with 0 orphan drug designations across 4 rare diseases, including 5 FDA-approved therapies. Active clinical trials in 3 indications.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| multiple system atrophy | - | Des.TrialAppr. |
| muscular dystrophy | - | Des.TrialAppr. |
| type 2 diabetes mellitus | FENOFIBRATE | Des.TrialAppr. |
| urea cycle disorder | GLYCEROL PHENYLBUTYRATE | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
14
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
14
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio